Published in Infect Immun on July 01, 1999
Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest (2002) 5.94
Determinants of acquisition and carriage of Staphylococcus aureus in infancy. J Clin Microbiol (2003) 1.87
Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract. Infect Immun (2000) 1.84
Determinants of Staphylococcus aureus nasal carriage. Clin Diagn Lab Immunol (2001) 1.80
Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest (2002) 1.67
Human factor in Staphylococcus aureus nasal carriage. Infect Immun (2004) 1.64
Endogenous lung stem cells and contribution to disease. J Pathol (2009) 1.50
Characterization of the mouse beta defensin 1, Defb1, mutant mouse model. Infect Immun (2002) 1.49
Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease. Am J Respir Cell Mol Biol (2006) 1.39
A mutation in the sap operon attenuates survival of nontypeable Haemophilus influenzae in a chinchilla model of otitis media. Infect Immun (2005) 1.37
Expression of C-reactive protein in the human respiratory tract. Infect Immun (2001) 1.31
Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. Infect Immun (2002) 1.30
Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect Immun (2002) 1.24
The lactoperoxidase system links anion transport to host defense in cystic fibrosis. FEBS Lett (2006) 1.23
Different type 1 fimbrial genes and tropisms of commensal and potentially pathogenic Actinomyces spp. with different salivary acidic proline-rich protein and statherin ligand specificities. Infect Immun (2001) 1.22
Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infection. BMC Infect Dis (2002) 1.20
Regulatory adaptation of Staphylococcus aureus during nasal colonization of humans. PLoS One (2010) 1.19
Hemoglobin promotes Staphylococcus aureus nasal colonization. PLoS Pathog (2011) 1.17
Staphylococcus aureus nasal carriage and its contributing factors. Future Microbiol (2009) 1.11
Antimycobacterial agent based on mRNA encoding human beta-defensin 2 enables primary macrophages to restrict growth of Mycobacterium tuberculosis. Infect Immun (2001) 1.08
pH modulates the activity and synergism of the airway surface liquid antimicrobials β-defensin-3 and LL-37. Proc Natl Acad Sci U S A (2014) 1.03
Host- and microbe determinants that may influence the success of S. aureus colonization. Front Cell Infect Microbiol (2012) 1.03
Suppression of innate immunity by a nasal carriage strain of Staphylococcus aureus increases its colonization on nasal epithelium. Immunology (2007) 1.01
IsdA protects Staphylococcus aureus against the bactericidal protease activity of apolactoferrin. Infect Immun (2008) 1.00
Mutations of the Listeria monocytogenes peptidoglycan N-deacetylase and O-acetylase result in enhanced lysozyme sensitivity, bacteriolysis, and hyperinduction of innate immune pathways. Infect Immun (2011) 0.98
Differences between Staphylococcus aureus isolates from medical and nonmedical hospital personnel. J Clin Microbiol (2002) 0.98
Airway acidification initiates host defense abnormalities in cystic fibrosis mice. Science (2016) 0.97
Peptide-based Antifungal Therapies against Emerging Infections. Drugs Future (2010) 0.97
Exoproteome of Staphylococcus aureus reveals putative determinants of nasal carriage. J Proteome Res (2011) 0.95
Defensins as anti-inflammatory compounds and mucosal adjuvants. Future Microbiol (2010) 0.95
Nutrient limitation governs Staphylococcus aureus metabolism and niche adaptation in the human nose. PLoS Pathog (2014) 0.93
A model for antimicrobial gene therapy: demonstration of human beta-defensin 2 antimicrobial activities in vivo. Hum Gene Ther (2002) 0.91
Genome sequencing and analysis reveals possible determinants of Staphylococcus aureus nasal carriage. BMC Genomics (2008) 0.91
Longitudinal genetic analyses of Staphylococcus aureus nasal carriage dynamics in a diverse population. BMC Infect Dis (2013) 0.89
C3 promotes clearance of Klebsiella pneumoniae by A549 epithelial cells. Infect Immun (2004) 0.88
Antimicrobial peptide defensin: identification of novel isoforms and the characterization of their physiological roles and their significance in the pathogenesis of diseases. Proc Jpn Acad Ser B Phys Biol Sci (2012) 0.87
Pathogenesis of cystic fibrosis airways disease. Trans Am Clin Climatol Assoc (2001) 0.87
Antimicrobial lipids: novel innate defense molecules are elevated in sinus secretions of patients with chronic rhinosinusitis. Am J Rhinol Allergy (2010) 0.87
Fatal attraction evaded. How pathogenic bacteria resist cationic polypeptides. J Exp Med (2001) 0.87
Characterization of the retrocyclin analogue RC-101 as a preventative of Staphylococcus aureus nasal colonization. Antimicrob Agents Chemother (2011) 0.82
Proteomic analysis of egg white heparin-binding proteins: towards the identification of natural antibacterial molecules. Sci Rep (2016) 0.82
Human antimicrobial proteins in ear wax. Eur J Clin Microbiol Infect Dis (2011) 0.81
Subversion of interleukin-1-mediated host defence by a nasal carrier strain of Staphylococcus aureus. Immunology (2008) 0.80
Expression of human beta-defensin 2 in human nasal mucosa. Eur Arch Otorhinolaryngol (2003) 0.80
Evidence and Role for Bacterial Mucin Degradation in Cystic Fibrosis Airway Disease. PLoS Pathog (2016) 0.80
Persistent Staphylococcus aureus colonization is not a strongly heritable trait in Amish families. PLoS One (2011) 0.79
A novel siderophore system is essential for the growth of Pseudomonas aeruginosa in airway mucus. Sci Rep (2015) 0.79
Clinical application of human β-defensin and CD14 gene polymorphism in evaluating the status of chronic inflammation. J Transl Med (2012) 0.79
Assessment of epithelial innate antimicrobial factors in sinus tissue from patients with and without chronic rhinosinusitis. Int Forum Allergy Rhinol (2014) 0.78
Cervical mucus properties stratify risk for preterm birth. PLoS One (2013) 0.78
Host innate inflammatory factors and staphylococcal protein A influence the duration of human Staphylococcus aureus nasal carriage. Mucosal Immunol (2016) 0.77
The nasal delivery of nanoencapsulated statins - an approach for brain delivery. Int J Nanomedicine (2016) 0.77
Structure of the Neisseria Adhesin Complex Protein (ACP) and its role as a novel lysozyme inhibitor. PLoS Pathog (2017) 0.75
Effects of aerobic exercise on lipid-effector molecules of the innate immune response. Med Sci Sports Exerc (2014) 0.75
Interleukin-17A (IL-17A) and IL-17F Are Critical for Antimicrobial Peptide Production and Clearance of Staphylococcus aureus Nasal Colonization. Infect Immun (2016) 0.75
Selected Factors of Innate Immunity in Healthy Individuals with S. aureus Nasal Carriage. Front Microbiol (2016) 0.75
Characterization of released polypeptides during an interferon-γ-dependent antibacterial response in airway epithelial cells. J Interferon Cytokine Res (2012) 0.75
Short Palate, Lung, and Nasal Epithelial Clone 1 Has Antimicrobial and Antibiofilm Activities against the Burkholderia cepacia Complex. Antimicrob Agents Chemother (2016) 0.75
Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem (1987) 59.79
Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev (1997) 12.33
Serum and urinary lysozyme (muramidase) in monocytic and monomyelocytic leukemia. J Exp Med (1966) 9.20
Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest (1985) 8.63
A peptide antibiotic from human skin. Nature (1997) 7.64
Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell (1996) 6.84
Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell (1998) 6.72
Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun (1983) 6.24
Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A (1998) 3.85
Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids. Proc Natl Acad Sci U S A (1988) 3.83
Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest (1998) 3.78
Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett (1996) 3.39
Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest (1991) 2.54
Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J Clin Invest (1997) 2.47
Transcriptional activation of mucin by Pseudomonas aeruginosa lipopolysaccharide in the pathogenesis of cystic fibrosis lung disease. Proc Natl Acad Sci U S A (1997) 2.24
Human airway epithelia express a beta-defensin. Am J Respir Cell Mol Biol (1997) 2.07
Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation. Gene (1998) 1.99
Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci U S A (1995) 1.97
Interaction of a salivary mucin-secretory immunoglobulin A complex with mucosal pathogens. Infect Immun (1991) 1.93
Designer assays for antimicrobial peptides. Disputing the "one-size-fits-all" theory. Methods Mol Biol (1997) 1.79
Effects of pH and salinity on the antimicrobial properties of clavanins. Infect Immun (1997) 1.75
Antimicrobial peptides of phagocytes and epithelia. Semin Hematol (1997) 1.50
Staphylococcus aureus binding to human nasal mucin. Infect Immun (1996) 1.50
Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr (1995) 1.40
Comparison of the opsonic activity of human surfactant protein A for Staphylococcus aureus and Streptococcus pneumoniae with rabbit and human macrophages. J Infect Dis (1993) 1.38
Regulation of human airway surface liquid. Respir Physiol (1995) 1.33
Pathophysiology of rhinitis. Lactoferrin and lysozyme in nasal secretions. J Clin Invest (1989) 1.24
Estimation of nasal epithelial lining fluid using urea as a marker. J Allergy Clin Immunol (1993) 1.12
Quantitative composition of nasal secretions in normal subjects. J Lab Clin Med (1972) 1.08
Secretion of type II phospholipase A2 and cryptdin by rat small intestinal Paneth cells. Infect Immun (1996) 1.08
The effects of sinus bacteria on human ciliated nasal epithelium in vitro. Otolaryngol Head Neck Surg (1988) 1.02
Characterization of phospholipase A2 from human nasal lavage. Am J Respir Cell Mol Biol (1994) 1.00
Human nasal respiratory secretions and host defense. Am Rev Respir Dis (1991) 0.94
Pathogenesis of bacterial bronchitis in cystic fibrosis. Pediatr Infect Dis J (1997) 0.92
Physiological regulation of the secretion of histatins and statherins in human parotid saliva. J Dent Res (1994) 0.90
Genetics of salivary protein polymorphisms. Crit Rev Oral Biol Med (1993) 0.89
Detection of anionic antimicrobial peptides in ovine bronchoalveolar lavage fluid and respiratory epithelium. Infect Immun (1998) 0.88
Two-dimensional gel electrophoresis of nasal and bronchoalveolar lavage fluids after occupational exposure. Electrophoresis (1995) 0.87
Cloning of beta-microseminoprotein of the rat: a rapidly evolving mucosal surface protein. Arch Biochem Biophys (1996) 0.86
Human nasal host defense and sinusitis. J Allergy Clin Immunol (1992) 0.86
The pathophysiology of rhinitis. III. The control of IgG secretion. J Allergy Clin Immunol (1989) 0.84
Immunohistochemical and in situ hybridization studies of beta-microseminoprotein in the human gastric mucosa. Histochem J (1998) 0.81
Group II phospholipase A2 in nasal fluid, mucosa and paranasal sinuses. Acta Otolaryngol (1997) 0.81
Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest (1985) 8.63
Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem (2000) 8.39
Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol (1993) 5.36
Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest (1989) 5.21
An antimicrobial activity of cytolytic T cells mediated by granulysin. Science (1998) 5.02
Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci U S A (1990) 3.90
Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A (1998) 3.85
Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest (1998) 3.78
Primary structures of three human neutrophil defensins. J Clin Invest (1985) 3.70
Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol (1999) 3.39
The multifaceted Paneth cell. Cell Mol Life Sci (2002) 3.11
Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol (1999) 3.05
A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol (1990) 2.98
Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis (2009) 2.55
Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest (1989) 2.50
Defensins: endogenous antibiotic peptides of animal cells. Cell (1991) 2.45
Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity. J Immunol (2001) 2.38
Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in E. coli by multiple-wavelength spectrophotometry. J Immunol Methods (1988) 2.31
Direct inactivation of viruses by MCP-1 and MCP-2, natural peptide antibiotics from rabbit leukocytes. J Virol (1985) 2.31
Defensins and other endogenous peptide antibiotics of vertebrates. J Leukoc Biol (1995) 2.25
Broad-spectrum antimicrobial activity of human intestinal defensin 5. Infect Immun (1997) 2.22
Modulation of the in vitro candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. J Clin Invest (1988) 2.18
Discovery of new human beta-defensins using a genomics-based approach. Gene (2001) 2.08
Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect Immun (1987) 2.07
Activity of rabbit leukocyte peptides against Candida albicans. Infect Immun (1985) 2.05
In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood (1986) 2.01
Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation. Gene (1998) 1.99
Antimicrobial polypeptides of human neutrophils. Blood (1990) 1.98
Neutrophils and host defense. Ann Intern Med (1988) 1.92
Correlation of binding of rabbit granulocyte peptides to Candida albicans with candidacidal activity. Infect Immun (1985) 1.89
Neutrophil defensins: purification, characterization, and antimicrobial testing. Methods Enzymol (1994) 1.88
The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry. Genomics (1997) 1.86
Localization of human intestinal defensin 5 in Paneth cell granules. Infect Immun (1997) 1.84
In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis (1986) 1.84
Determinants of Staphylococcus aureus nasal carriage. Clin Diagn Lab Immunol (2001) 1.80
Posttranslational processing of defensins in immature human myeloid cells. Blood (1992) 1.68
Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol (1989) 1.64
Mechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity. J Immunol (1988) 1.64
Isolation and characterization of human defensin cDNA clones. Proc Natl Acad Sci U S A (1988) 1.61
Defensin-rich dense granules of human neutrophils. Blood (1987) 1.59
Localized antimicrobial peptide expression in human gingiva. J Periodontal Res (2001) 1.58
Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. J Lab Clin Med (1993) 1.57
Defensins: a family of antimicrobial and cytotoxic peptides. Toxicology (1994) 1.53
Purification and antimicrobial properties of three defensins from rat neutrophils. Infect Immun (1989) 1.46
Defensins and innate host defence of the gastrointestinal tract. Gut (1999) 1.41
Porcine polymorphonuclear leukocytes generate extracellular microbicidal activity by elastase-mediated activation of secreted proprotegrins. Infect Immun (1997) 1.40
Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds. Blood (2001) 1.39
Granulysin, a T cell product, kills bacteria by altering membrane permeability. J Immunol (2000) 1.39
Regulation of human beta-defensins by gastric epithelial cells in response to infection with Helicobacter pylori or stimulation with interleukin-1. Infect Immun (2000) 1.33
In human epidermis, beta-defensin 2 is packaged in lamellar bodies. Exp Mol Pathol (2003) 1.33
Intramolecular inhibition of human defensin HNP-1 by its propiece. J Clin Invest (1996) 1.32
Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare. Infect Immun (1992) 1.32
Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics (1999) 1.31
Activated alpha 2-macroglobulin is a principal defensin-binding protein. Am J Respir Cell Mol Biol (1991) 1.30
A cost-benefit analysis of scaling up tuberculosis control in India. Int J Tuberc Lung Dis (2011) 1.28
Defensins mediate the microbicidal activity of human neutrophil granule extract against Acinetobacter calcoaceticus. Infect Immun (1987) 1.27
Isolation of human intestinal defensins from ileal neobladder urine. FEBS Lett (1998) 1.26
Endogenous vertebrate antibiotics. Defensins, protegrins, and other cysteine-rich antimicrobial peptides. Ann N Y Acad Sci (1996) 1.22
Direct cytotoxicity of polymorphonuclear leukocyte granule proteins to human lung-derived cells and endothelial cells. Am Rev Respir Dis (1990) 1.21
Oxygen-independent bactericidal systems. Mechanisms and disorders. Hematol Oncol Clin North Am (1988) 1.21
Human neutrophil defensin and serpins form complexes and inactivate each other. Am J Respir Cell Mol Biol (1995) 1.20
The structure of porcine protegrin genes. FEBS Lett (1995) 1.19
Molecular cloning of the rat metallothionein 1 (MT-1) mRNA sequence. DNA (1983) 1.17
Newborn rabbit alveolar macrophages are deficient in two microbicidal cationic peptides, MCP-1 and MCP-2. Am Rev Respir Dis (1985) 1.17
Cationic defensins arise from charge-neutralized propeptides: a mechanism for avoiding leukocyte autocytotoxicity? J Leukoc Biol (1992) 1.16
The opsonizing ligand on Salmonella typhimurium influences incorporation of specific, but not azurophil, granule constituents into neutrophil phagosomes. J Cell Biol (1989) 1.16
Protegrins: new antibiotics of mammalian origin. Expert Opin Investig Drugs (2000) 1.15
Purification and characterization of a major phosphatidylserine-binding phosphoprotein from human platelets. Biochem J (1990) 1.14
In vitro sensitivity of oral, gram-negative, facultative bacteria to the bactericidal activity of human neutrophil defensins. Infect Immun (1990) 1.13
An enzyme immunoassay for human defensins. J Immunol Methods (1991) 1.12
A 450-kb contig of defensin genes on human chromosome 8p23. Gene (1999) 1.12
Purification and characterization of defensins from cystic fibrosis sputum. Inflamm Res (1997) 1.11
Immunohistochemical localization of defensin in human coronary vessels. Am J Pathol (1997) 1.11
Detection of beta-defensins secreted by human oral epithelial cells. J Immunol Methods (2001) 1.09
Polymorphic expression of defensins in neutrophils from outbred rats. Infect Immun (1990) 1.08
Differential scanning microcalorimetry indicates that human defensin, HNP-2, interacts specifically with biomembrane mimetic systems. Biochemistry (1997) 1.07
The pro region of human neutrophil defensin contains a motif that is essential for normal subcellular sorting. Blood (1995) 1.07
Capacity building for international tuberculosis control through operations research training. Int J Tuberc Lung Dis (2005) 1.06
Assignment of defensin gene(s) to human chromosome 8p23. Genomics (1989) 1.06
Porcine epithelial beta-defensin 1 is expressed in the dorsal tongue at antimicrobial concentrations. Infect Immun (1999) 1.06
Microanalysis of antimicrobial properties of human fluids. J Microbiol Methods (2000) 1.03
Inhibition of protein kinase C by defensins, antibiotic peptides from human neutrophils. Biochem Pharmacol (1988) 1.02
Human antimicrobial peptides: analysis and application. Biotechniques (2000) 1.02
Molecular cloning and tissue expression of porcine beta-defensin-1. FEBS Lett (1998) 1.01
An in vitro study of antibacterial properties of the cervical mucus plug in pregnancy. Am J Obstet Gynecol (2001) 1.01
Human beta defensin is absent in burn blister fluid. Burns (2000) 1.01
Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood (1999) 1.01
Iron-regulatory protein hepcidin is increased in female athletes after a marathon. Eur J Appl Physiol (2005) 1.01
Synergistic cytolysis mediated by hydrogen peroxide combined with peptide defensins. Cell Immunol (1988) 1.00
Paneth cells--guardians of the gut cell hatchery. Nat Immunol (2000) 1.00
Inhibition of intracellular Histoplasma capsulatum replication by murine macrophages that produce human defensin. Infect Immun (1994) 1.00
Identification of defensin binding to C1 complement. FEBS Lett (1994) 0.98
Calcitermin, a novel antimicrobial peptide isolated from human airway secretions. FEBS Lett (2001) 0.98
Defensins: endogenous antibiotic peptides from human leukocytes. Ciba Found Symp (1992) 0.96
The structure of neutrophil defensin genes. FEBS Lett (1993) 0.96
Beta-defensin expression in human mammary gland epithelia. Pediatr Res (2000) 0.95
Are all patients diagnosed with tuberculosis in Indian medical colleges referred to the RNTCP? Int J Tuberc Lung Dis (2012) 0.95
The NMR structure of human beta-defensin-2 reveals a novel alpha-helical segment. Biochemistry (2001) 0.95
Innate immunity: from plants to humans. Immunol Today (2000) 0.94